It establishes the scientific rationale for targeting cellular senescence as a driver of aging and age-related diseases
[1] [2] GLP-1 medications work through several complementary mechanisms: Enhancing insulin secretion : They stimulate the pancreas to release insulin when blood glucose levels are elevated, helping to lower blood sugar in a glucose-dependent manner Suppressing glucagon release : They reduce the secretion of glucagon, a hormone that raises blood glucose, thereby preventing excessive glucose production by the liver Slowing gastric emptying : They delay the rate at which food leaves the stomach, leading to more gradual glucose absorption and increased feelings of fullness Reducing appetite : They act on areas of the brain involved in appetite regulation, helping to decrease food intake [2] [22] Commonly prescribed GLP-1 receptor agonists in the UK include semaglutide (Ozempic for diabetes, Wegovy for weight management, Rybelsus as an oral formulation), dulaglutide (Trulicity), liraglutide (Victoza for diabetes, Saxenda for weight management), and exenatide (Byetta, Bydureon)
Additionally, a negative correlation between SAT adipogenesis, but not VAT, and systemic IR was observed [62]
[23] [13] Nausea is most common during the first week of GLP-1 therapy and typically improves significantly within 24 weeks as your body adjusts to the medication
This double effect keeps your blood sugar levels in check
)
